KR20210106997A - 아레나바이러스 감염 치료용 화합물 - Google Patents
아레나바이러스 감염 치료용 화합물 Download PDFInfo
- Publication number
- KR20210106997A KR20210106997A KR1020217017726A KR20217017726A KR20210106997A KR 20210106997 A KR20210106997 A KR 20210106997A KR 1020217017726 A KR1020217017726 A KR 1020217017726A KR 20217017726 A KR20217017726 A KR 20217017726A KR 20210106997 A KR20210106997 A KR 20210106997A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- independently selected
- alkyl
- group
- nhr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c(cc1)ccc1Br Chemical compound *c(cc1)ccc1Br 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776390P | 2018-12-06 | 2018-12-06 | |
| US62/776,390 | 2018-12-06 | ||
| PCT/US2019/064223 WO2020117794A1 (en) | 2018-12-06 | 2019-12-03 | Compounds for the treatment of arenavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210106997A true KR20210106997A (ko) | 2021-08-31 |
Family
ID=70975517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217017726A Ceased KR20210106997A (ko) | 2018-12-06 | 2019-12-03 | 아레나바이러스 감염 치료용 화합물 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3890731A4 (https=) |
| JP (1) | JP7675009B2 (https=) |
| KR (1) | KR20210106997A (https=) |
| CN (1) | CN113329750B (https=) |
| AR (1) | AR117228A1 (https=) |
| AU (1) | AU2019393784B2 (https=) |
| BR (1) | BR112021010909A2 (https=) |
| EA (1) | EA202191001A1 (https=) |
| MX (2) | MX2021005234A (https=) |
| WO (1) | WO2020117794A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217490B (zh) * | 2023-02-03 | 2025-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种苯并咪唑类化合物及其制备方法和应用 |
| EP4434972A1 (en) * | 2023-03-22 | 2024-09-25 | Eberhard-Karls-Universität Tübingen | Atm kinase inhibitors |
| WO2025137345A1 (en) * | 2023-12-20 | 2025-06-26 | Arisan Therapeutics Inc. | Crystalline forms of an imidazopyridine derivative |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| AP3675A (en) * | 2012-02-17 | 2016-04-15 | Kineta Four Llc | Antiviral drugs for treatment of arenavirus infection |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
-
2019
- 2019-12-02 AR ARP190103517A patent/AR117228A1/es unknown
- 2019-12-03 MX MX2021005234A patent/MX2021005234A/es unknown
- 2019-12-03 CN CN201980080594.2A patent/CN113329750B/zh active Active
- 2019-12-03 EA EA202191001A patent/EA202191001A1/ru unknown
- 2019-12-03 EP EP19892030.8A patent/EP3890731A4/en active Pending
- 2019-12-03 WO PCT/US2019/064223 patent/WO2020117794A1/en not_active Ceased
- 2019-12-03 AU AU2019393784A patent/AU2019393784B2/en active Active
- 2019-12-03 JP JP2021525159A patent/JP7675009B2/ja active Active
- 2019-12-03 BR BR112021010909-9A patent/BR112021010909A2/pt unknown
- 2019-12-03 KR KR1020217017726A patent/KR20210106997A/ko not_active Ceased
-
2021
- 2021-05-04 MX MX2024013042A patent/MX2024013042A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3890731A4 (en) | 2022-08-17 |
| MX2021005234A (es) | 2021-08-11 |
| AU2019393784B2 (en) | 2025-06-12 |
| JP2022509763A (ja) | 2022-01-24 |
| MX2024013042A (es) | 2024-12-06 |
| CA3118765A1 (en) | 2020-06-11 |
| EA202191001A1 (ru) | 2021-08-16 |
| CN113329750B (zh) | 2025-10-17 |
| AU2019393784A1 (en) | 2021-05-27 |
| EP3890731A1 (en) | 2021-10-13 |
| JP7675009B2 (ja) | 2025-05-12 |
| WO2020117794A1 (en) | 2020-06-11 |
| CN113329750A (zh) | 2021-08-31 |
| BR112021010909A2 (pt) | 2021-08-24 |
| AR117228A1 (es) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11352328B2 (en) | Heterocyclic compounds for the treatment of arenavirus | |
| AU2018331172B2 (en) | Influenza virus replication inhibitor and use thereof | |
| CN112940010B (zh) | 经取代的多环性吡啶酮衍生物及其前药 | |
| KR101930106B1 (ko) | 지질 합성의 헤테로사이클릭 조절자 | |
| TW202202148A (zh) | 用於治療covid-19之化合物及方法 | |
| WO2019018185A1 (en) | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS | |
| BR112014007134B1 (pt) | Usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso do composto para fabricação de um medicamento para tratar ou prevenir infecções flavivirais | |
| CA2764653A1 (en) | Tetracyclic compounds | |
| EP3405183A1 (en) | Adamatane derivatives for the treatment of filovirus infection | |
| EP2997028A1 (en) | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | |
| KR20210106997A (ko) | 아레나바이러스 감염 치료용 화합물 | |
| TW201138786A (en) | Therapeutic compounds | |
| ES2938335T3 (es) | Nuevo derivado de pirrolopiridina, método para producir el mismo y uso del mismo | |
| Ahmed et al. | Targeting chikungunya virus replication by benzoannulene inhibitors | |
| JP6859358B2 (ja) | テトラヒドロインダゾール及びその医学的使用 | |
| US12419865B2 (en) | Compounds for the treatment of arenavirus infection | |
| CA3118765C (en) | Compounds for the treatment of arenavirus infection | |
| CN114466848A (zh) | 抗细菌化合物 | |
| OA20266A (https=) | ||
| EA044865B1 (ru) | Соединения для лечения аренавирусной инфекции | |
| WO2021262426A9 (en) | Adamantane amides and thioamides for the treatment of ebolavirus infection | |
| WO2021194954A1 (en) | Substituted azole dione compounds with antiviral activity | |
| Wang et al. | Lipid-Optimized Sulfone-Bridged Cidofovir Prodrugs as Potent Antivirals Against Orthopoxviruses | |
| US20240131007A1 (en) | Methods and compositions for picornavirus anti-viral agents | |
| CN111868022A (zh) | 以锌结合剂为基础的ebna1特异性化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |